Skip to content
✕
Internet Explorer is no longer supported by this website.
For optimal browsing we recommend using
Chrome
,
Firefox
or
Safari
.
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Menu
Search
Toggle Menu
Change Country
Our Stories
Latest News
Innovation
Caring & Giving
Personal Stories
Health & Wellness
Our Heritage
Our Company
About J&J
Our Credo
Our Leadership Team
Code of Business Conduct
Corporate Reports
Diversity, Equity & Inclusion
ESG Policies & Positions
Innovation at J&J
Digital Solutions
J&J Health and Wellness Solutions
Office of the Chief Medical Officer
Veterans, Military & Military Families
Products
MedTech
Pharmaceutical Products
Suppliers
Responsible Supply Base
Supplier-Enabled Innovation
Supplier Resources
Careers
Life at J&J
Diversity, Equity and Inclusion
Career Areas of Impact
Students
Re-Ignite Program
Contract & Freelance Partner Opportunities
Career Stories
Media Center
Investors
2023 Annual Meeting of Shareholders
Corporate Governance
Quarterly Results
SEC Filings
News Releases
Pharmaceutical Pipeline
2022 Janssen Transparency Report
2021 Health for Humanity Report
ESG Investor Update
ESG Resources
Stock Information
Webcasts & Presentations
Investor Fact Sheet
Our Societal Impact
Global Community Impact
Global Public Health
Global Environmental Sustainability
Close Countries Menu
Explore more Johnson & Johnson sites:
China
France
Germany
India
Japan
Russia
Switzerland
German
English
French
United Kingdom
United States
Close Search Menu
Search input
Jump to:
Oncology
Home
Latest News
Resources
Lung Cancer Initiative
Language
English
Spanish
Oncology
Latest News
Latest News
The latest oncology news across Johnson & Johnson.
Latest News
May 02, 2023
Janssen Enters Worldwide Collaboration and License Agreement with Cellular Biomedicine Group to Develop Next Generation CAR-T Therapies
Latest News
April 30, 2023
Janssen Reports First Results from Phase 2 SunRISe-1 Study of TAR-200 and Anti- PD-1 Antibody Cetrelimab in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer
Innovation
April 21, 2023
Janssen Marks First Approval Worldwide for AKEEGA
®
(Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorization for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations
Latest News
April 06, 2023
Update on IMBRUVICA
®
(ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications
Latest News
April 03, 2023
ERLEADA
®
(apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option, Now Available in the U.S.
Latest News
March 29, 2023
New RYBREVANT
®
(amivantamab-vmjw) Data Showed Long-Term Clinical Response and Safety in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Who Have Failed Prior Platinum-Based Chemotherapy
Latest News
March 01, 2023
Janssen Submits New Drug Application to the U.S. Food and Drug Administration Seeking Approval of Niraparib and Abiraterone Acetate Dual-Action Tablet, Plus Prednisone, as a First-Line Targeted Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with BRCA Gene Mutations
Latest News
February 27, 2023
Janssen Receives Positive CHMP Opinion for AKEEGA
®
(Niraparib and Abiraterone Acetate Dual Action Tablet) Plus Prednisone or Prednisolone for the Treatment of Adult Patients with BRCA1/2 Gene-Mutated Metastatic Castration Resistant Prostate Cancer
Latest News
February 16, 2023
Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
Latest News
February 13, 2023
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
Latest News
January 27, 2023
Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI
®
(cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Latest News
December 12, 2022
Real-World Study Shows Patients Treated with IMBRUVICA
®
(ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on Acalabrutinib in First-line Chronic Lymphocytic Leukemia
Latest News
December 12, 2022
Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX
®
(daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
Latest News
December 10, 2022
Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI™ (teclistamab-cqyv) in Combination with DARZALEX
FASPRO
®
(daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
Latest News
December 10, 2022
Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma
Load More
Back to top
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue